0
Diffuse Lung Disease |

Erythropoietin Inhibits the Expression of Erythropoietin Receptor (EPO-R) in Bleomycin (BLM)-Induced Pulmonary Fibrosis in Rats

Drosos Tsavlis*, PhD; Anna Tzoumaka, MD; Georgia Kokaraki, PhD; Kokona Koliakos-Kouzi, PhD; Dimitrios Koutsonikolas, PhD; Anastasia Tektonidou, MSCE; Afroditi Papadopoulou, MD; Evangelia Spandou, PhD
Author and Funding Information

Aristotle University of Thessaloniki, Thessaloniki, Greece


Chest. 2012;142(4_MeetingAbstracts):448A. doi:10.1378/chest.1388785
Text Size: A A A
Published online

Abstract

SESSION TYPE: ILD Posters

PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM

PURPOSE: Pulmonary Fibrosis is characterized by apoptosis, inflammation, excessive collagen deposition and fibroplasts' proliferation.The EPO-R is a very well known enzyme which plays an important role in the fibrotic-apoptotic pathway. Erythropoietin (EPO) is a multiple functional cytokine with anti-apoptotic, anti-oxidative and anti-inflammatory properties.We looked for the effect of EPO on BLM-induced lung fibrosis, by examining the expression of EPO-R in the lung tissue of rats.

METHODS: Fifty Wistar rats (300gr) were divided into five groups of 10 animals each: 1) control animals, 2) intratracheal (i.t) and intraperitoneal (i.p) injection of saline (0.5ml/kg), 3) BLM hydrochloride (7.5mg/kg) i.t injection, 4) BLM hydrochloride (7.5mg/kg) i.t injection followed by EPO i.p injection (2000 iu/kg), 5) saline (0.5ml/kg) i.t injection followed by EPO i.p injection (2000 iu/kg). All rats were sacrified after 14 days. Immunohistochemical evaluation was performed for the expression of EPO-R. A scale of 4 grades was used for the evaluation of the results: 0-25% (A), 25-50% (B), 50-75% (C) and 75-100% (D).

RESULTS: In groups 1,2 and 5 (control groups), EPO-R was expressed in the lower grades A (80%) and B (20%). In group 3 (BLM group), EPO-R was expressed in the high grades B (20%), C (70%) and D (10%). In group 4 (BLM+EPO group), EPO-R was expressed only in the low grades A (50%) and B (50%). The expression of EPO-R took place in the high grades for BLM group and in the lower grades for BLM+EPO group (p<0.05).

CONCLUSIONS: BLM injection followed by EPO injection resulted in significant lower expression of EPO-R compared to the expression of EPO-R in BLM group.

CLINICAL IMPLICATIONS: The protective effect of EPO on Pulmonary Fibrosis is obvious and the underlying mechanisms must be further clarified in order to achieve a treatment for this lethal lung disease

DISCLOSURE: The following authors have nothing to disclose: Drosos Tsavlis, Anna Tzoumaka, Georgia Kokaraki, Kokona Koliakos-Kouzi, Dimitrios Koutsonikolas, Anastasia Tektonidou, Afroditi Papadopoulou, Evangelia Spandou

No Product/Research Disclosure Information

Aristotle University of Thessaloniki, Thessaloniki, Greece

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543